Mingzhao Xing

发表

Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.

J. Bishop, Jiajun Zhao, M. Xing, 2015, The Journal of clinical endocrinology and metabolism.

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

P. Ladenson, D. Clark, A. Dackiw, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes.

Guojun Wu, B. Trink, Shuiying Hu, 2005, The Journal of clinical endocrinology and metabolism.

BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-Analysis

J. Bishop, M. Xing, K. Carson, 2012, Medicine.

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

M. Xing, Mingzhao Xing, 2007, Endocrine reviews.

Progress in molecular-based management of differentiated thyroid cancer

M. Schlumberger, B. Haugen, M. Xing, 2013, The Lancet.

Thyroid Cancer 2 Progress in molecular-based management of diff erentiated thyroid cancer

M. Schlumberger, B. Haugen, M. Xing, 2013 .

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

J. Fagin, L. Yip, Y. Shong, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular pathogenesis and mechanisms of thyroid cancer

M. Xing, Mingzhao Xing, Mingzhao Xing, 2013, Nature Reviews Cancer.

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.

J. Bishop, S. Pai, M. Xing, 2013, Endocrine-related cancer.

Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.

M. Xing, Ermal Bojdani, A. K. Murugan, 2010, Biochemical and biophysical research communications.

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

P. Ladenson, J. Califano, D. Sidransky, 2005, The Journal of clinical endocrinology and metabolism.

BRAF mutation in papillary thyroid carcinoma.

P. Ladenson, Zhongmin Guo, B. Trink, 2003, Journal of the National Cancer Institute.

Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.

P. Ladenson, Guojun Wu, Zhongmin Guo, 2005, The Journal of clinical endocrinology and metabolism.

The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer

L. Yip, Xiaopei Shen, Jiajun Zhao, 2017, The Journal of clinical endocrinology and metabolism.

BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma.

L. Yip, Xiaopei Shen, F. Vianello, 2019, European journal of cancer.

Somatic mutation and gain of copy number of PIK3CA in human breast cancer

Xin Huang, David Goldenberg, Aditi Chatterjee, 2005, Breast Cancer Research.

Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer.

P. Ladenson, A. Carvalho, D. Sidransky, 2006, The Journal of clinical endocrinology and metabolism.

Estrogen receptor α induces prosurvival autophagy in papillary thyroid cancer via stimulating reactive oxygen species and extracellular signal regulated kinases.

G. Chen, A. Vlantis, M. Xing, 2015, The Journal of clinical endocrinology and metabolism.

Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing.

P. Ladenson, Zhongmin Guo, J. Califano, 2003, Cancer research.

A novel role for thyroid‐stimulating hormone: Up‐regulation of hepatic 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme a reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate–responsive element binding protein pathway

G. Ning, Jiajun Zhao, Xiaoying Li, 2010, Hepatology.

Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality

Tao Zhang, P. Ladenson, J. Bishop, 2017, JAMA oncology.

Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.

Peng Hou, Guojun Wu, P. Hou, 2009, Cancer research.

Genetic-guided Risk Assessment and Management of Thyroid Cancer.

M. Xing, Mingzhao Xing, 2019, Endocrinology and metabolism clinics of North America.

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer

M. Xing, Rengyun Liu, Guangwu Zhu, 2018, Nature Communications.

Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness

J. Bishop, Xiaopei Shen, M. Xing, 2016, Oncotarget.

Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data

Ju Han Kim, Y. J. Chai, M. Xing, 2016, PloS one.

BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.

G. Chen, Zhongwei Lv, M. Xing, 2015, Endocrine-related cancer.

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

P. Ladenson, D. Clark, D. Sidransky, 2013, JAMA.

BRAFV600E mutation and papillary thyroid cancer: chicken or egg?

M. Xing, Mingzhao Xing, 2012, The Journal of clinical endocrinology and metabolism.

The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells

P. Hou, M. Xing, Dingxie Liu, 2012, Cell cycle.

Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.

P. Hou, M. Xing, Dingxie Liu, 2011, Endocrine-related cancer.

Genetic and Epigenetic Alterations in the MAP Kinase and PI3K/Akt Pathways in Thyroid Cancer

P. Ladenson, M. Xing, Mingzhao Xing, 2011 .

Induction of heparanase-1 expression by mutant B-Raf kinase: role of GA binding protein in heparanase-1 promoter activation.

M. Xing, Dingxie Liu, J. Tauler, 2010, Neoplasia.

Prognostic utility of BRAF mutation in papillary thyroid cancer

M. Xing, Mingzhao Xing, 2010, Molecular and Cellular Endocrinology.

Induction of Thyroid Gene Expression and Radioiodine Uptake in Melanoma Cells: Novel Therapeutic Implications

R. Wahl, P. Hou, M. Xing, 2009, PloS one.

Recent advances in molecular biology of thyroid cancer and their clinical implications.

M. Xing, Mingzhao Xing, 2008, Otolaryngologic clinics of North America.

Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.

P. Hou, M. Xing, Dingxie Liu, 2008, Endocrine-related cancer.

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

David Sidransky, Ning Jin, A. Dackiw, 2007, The Journal of clinical endocrinology and metabolism.

Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.

A. Dackiw, M. Xing, Dingxie Liu, 2007, The Journal of clinical endocrinology and metabolism.

BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.

M. Xing, Dingxie Liu, Zhi Liu, 2007, The Journal of clinical endocrinology and metabolism.

Functional Characterization of the T1799-1801del and G1799-1816ins BRAF Mutations in Papillary Thyroid Cancer

P. Hou, M. Xing, Dingxie Liu, 2007, Cell cycle.

The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer

M. Xing, Mingzhao Xing, 2005, Clinical endocrinology.

Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer.

P. Ladenson, D. Sidransky, M. Xing, 2004, The Journal of clinical endocrinology and metabolism.

Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis

Yoram Cohen, Giovanni Tallini, David Sidransky, 2004, Cancer Research.

PROGNOSTIC GENETIC MARKER-GUIDED RISK STRATIFICATION AND MANAGEMENT OF THYROID CANCER

M. Xing, Mingzhao Xing, 2019 .

Diagnostic and Prognostic Molecular Markers in Thyroid Cancer

M. Xing, Mingzhao Xing, 2016 .

CLINICAL ASPECTS OF BRAF MUTATION IN THYROID CANCER

M. Xing, Mingzhao Xing, 2010 .

Association of the T 1799 A BRAF mutation with tumor extrathyroidal invasion , higher peripheral platelet counts , and over-expression of platelet-derived growth factor-B in papillary thyroid cancer

P. Hou, M. Xing, Dingxie Liu, 2008 .

Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma

Jianhui Xu, M. Xing, Mingzhao Xing, 2015, Oncotarget.

Identification and characterization of novel PAX8 mutations in Congenital Hypothyroidism(CH) in a Chinese population

F. Wang, Shiguo Liu, M. Xing, 2017, Oncotarget.

DeltaNp63alpha up-regulates the Hsp70 gene in human cancer.

Guojun Wu, Zhongmin Guo, J. Califano, 2005, Cancer research.

Tumor‐specific changes in mtDNA content in human cancer

S. Sukumar, A. Chatterjee, D. Sidransky, 2005, International journal of cancer.

The sonic hedgehog signaling pathway stimulates anaplastic thyroid cancer cell motility and invasiveness by activating Akt and c-Met

M. Xing, Jin Ye, Xiulong Xu, 2016, Oncotarget.

Hypermethylation of the DNA mismatch repair gene hMLH1 and Its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer

P. Hou, M. Xing, W. Teng, 2008, Cancer.

Molecular Aberrance in Papillary Thyroid Microcarcinoma Bearing High Aggressiveness: Identifying a “Tibetan Mastiff Dog” From Puppies

M. Gao, Dapeng Li, Xiaolong Li, 2016, Journal of cellular biochemistry.

Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma

A. von Deimling, Guojun Wu, C. Hartmann, 2013, Cell cycle.

Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.

A. K. Murugan, Mingzhao Xing, 2011, Cancer research.

Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer

M. Xing, Dingxie Liu, A. K. Murugan, 2013, Endocrine-related cancer.

Mitochondrial DNA alterations in thyroid cancer

J. Califano, D. Sidransky, W. Westra, 2003, Journal of surgical oncology.

Oxidative stress: a new risk factor for thyroid cancer.

M. Xing, Mingzhao Xing, 2012, Endocrine-related cancer.

Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.

P. Hou, V. Vasko, M. Xing, 2008, The Journal of clinical endocrinology and metabolism.

Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.

L. Yip, Xiaopei Shen, F. Vianello, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent incidences and differential trends of thyroid cancer in the USA.

M. Xing, Yushan Mao, Mingzhao Xing, 2016, Endocrine-related cancer.

Acoustic Radiation Force Impulse Elastography in the Diagnosis of Thyroid Nodules: Useful or Not Useful?

Hui-Xiong Xu, M. Xing, Le-Hang Guo, 2015, Ultrasound in medicine & biology.

DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.

Qi-En Wang, M. Xing, Mingchuan Li, 2013, Endocrine-related cancer.

Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.

M. Xing, A. Alzahrani, Mingzhao Xing, 2013, Endocrine-related cancer.

The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

G. Ning, M. Xing, Dingxie Liu, 2011, The Journal of clinical endocrinology and metabolism.

BRAF mutation‐selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic‐potentiated synergism with the mTOR inhibitor temsirolimus

B. Trink, M. Xing, Dingxie Liu, 2010, International journal of cancer.

Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.

P. Hou, M. Xing, Ermal Bojdani, 2010, The Journal of clinical endocrinology and metabolism.

Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer.

P. Hou, M. Xing, W. Teng, 2009, The Journal of clinical endocrinology and metabolism.

BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management

M. Xing, Mingzhao Xing, 2009, Annals of surgical oncology.

Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.

M. Xing, Dingxie Liu, M. Xing, 2008, Thyroid : official journal of the American Thyroid Association.

DKK 3 is a potential tumor suppressor gene in papillary thyroid carcinoma

Qi-En Wang, M. Xing, Mingchuan Li, 2013 .

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.

M. Xing, W. Teng, Z. Shan, 2014, The Journal of clinical endocrinology and metabolism.

BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.

L. Yip, Xiaopei Shen, F. Vianello, 2018, Journal of the National Cancer Institute.

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.

Tae Yong Kim, S. Asa, K. Al-Kuraya, 2016, The Journal of clinical endocrinology and metabolism.

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.

J. Bishop, M. Zeiger, S. Pai, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.

M. Xing, Mingzhao Xing, 2010, Thyroid : official journal of the American Thyroid Association.

Decreased breast cancer-specific mortality risk in patients with a history of thyroid cancer

Xiaopei Shen, M. Xing, Weiwei Cheng, 2019, PloS one.

G. Ning, Jiajun Zhao, Xiaoying Li, 2010, Hepatology.

BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients

M. Xing, Fan Yang, O. Wang, 2016, Oncotarget.

Gene methylation in thyroid tumorigenesis.

M. Xing, Mingzhao Xing, 2007, Endocrinology.

Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer

J. Califano, W. Westra, M. Zeiger, 2006, International journal of cancer.

Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis.

P. Ladenson, Guojun Wu, D. Sidransky, 2003, Cancer research.

Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer

M. Xing, Mingzhao Xing, Mingzhao Xing, 2016, BMC Medicine.

High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.

Wei Wang, Bingyin Shi, Peng Hou, 2007, The Journal of clinical endocrinology and metabolism.

Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 Mutations in Thyroid Cancers

M. Xing, Jianli Dong, Jingwu Xie, 2011, Endocrine pathology.

Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3‐kinase/AKT signaling pathway in thyroid tumors

P. Hou, M. Xing, Meiju Ji, 2008, Cancer.

Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer

A. El‐Naggar, P. Hou, Shuiying Hu, 2007, Clinical Cancer Research.

Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.

M. Xing, Yong Lin, Xiaofei Jiang, 2008, Endocrine-related cancer.

The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer

Xiaopei Shen, M. Xing, Rengyun Liu, 2019, The Journal of Nuclear Medicine.

BRAF V600E mutation and papillary thyroid cancer.

M. Xing, Mingzhao Xing, 2013, JAMA.

TERT promoter mutations in thyroid cancer.

M. Xing, Mingzhao Xing, Rengyun Liu, 2016, Endocrine-related cancer.

The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.

M. Xing, Dingxie Liu, Ruixin Liu, 2012, The Journal of clinical endocrinology and metabolism.

Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer.

Andrew B. Sholl, A. Sholl, A. Boulares, 2015, Cancer letters.

Strong association of high urinary iodine with thyroid nodule and papillary thyroid cancer

M. Xing, F. Wang, Yangang Wang, 2014, Tumor Biology.

IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer

A. El‐Naggar, V. Vasko, M. Xing, 2010, Clinical Cancer Research.

Letter re: uncommon mutation but common amplifications of the PIK3CA gene in thyroid tumors.

P. Ladenson, Dingxie Liu, E. Mambo, 2005, The Journal of clinical endocrinology and metabolism.

Identification and Characterization of Two Novel Oncogenic mTOR Mutations

M. Xing, Rengyun Liu, A. K. Murugan, 2019, Oncogene.